Acrs stock zacks
ACRS Aclaris Therapeutics — Stock Price and ... - StockTwits Real-time trade and investing ideas on Aclaris Therapeutics ACRS from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Zacks Investment Research Lowers Aclaris Therapeutics ... Zacks Investment Research lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a report issued on Thursday, Zacks.com reports.. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. ACRS | Aclaris Therapeutics Inc. Profile | MarketWatch Nov 08, 2019 · Aclaris Therapeutics Inc. company facts, information and stock details by MarketWatch. View acrs business summary and other industry information.
ACRS Stock Quote - Aclaris Therapeutics, Inc. Common Stock ...
ACRS - Aclaris Therapeutics Summary, Stock ... - Benzinga Jan 01, 2010 · Aclaris Therapeutics (NASDAQ: ACRS) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Zacks ... Apr 08, 2020 · Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The Aclaris (ACRS) Upgraded to Buy: Here's Why Dec 24, 2019 · Investors might want to bet on Aclaris Therapeutics (ACRS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Finance - Zacks - Zacks Investment Research
Aclaris Therapeutics (ACRS) May Report Negative Earnings ...
Aclaris Therapeutics, Inc. - ACRS - Stock Price Today - Zacks View Aclaris Therapeutics, Inc. ACRS investment & stock information. Get the latest Aclaris Therapeutics, Inc. ACRS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. All News for ACRS : Aclaris Therapeutics, Inc. - Zacks.com What Makes Aclaris (ACRS) a New Buy Stock. by Zacks Equity Research Published on July 09,2019 . Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the ACRS: Aclaris Therapeutics, Inc. - Zacks Investment Research ACRS: Aclaris Therapeutics, Inc. - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Aclaris Therapeutics, Inc. from Zacks Investment Research
All News for ACRS : Aclaris Therapeutics, Inc. - Zacks.com
Mar 15, 2019 · Zacks Investment Research reports that the 2018 Price to Earnings ratio for ACRS is -1.49 vs. an industry ratio of -4.60, implying that they will have a higher earnings growth than their Analysts Anticipate Aclaris Therapeutics Inc (NASDAQ:ACRS ...
Aclaris Therapeutics, Inc. Common Stock (ACRS) Earnings ...
Analysts Anticipate Aclaris Therapeutics Inc (NASDAQ:ACRS ... Apr 07, 2020 · Equities analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Aclaris Therapeutics’ earnings, with the lowest EPS estimate coming in … Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Zacks ... Zacks Investment Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. The brokerage currently has $1.25 price objective on the biotechnology company’s stock. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, […] ACRS News Today (Aclaris Therapeutics) | MarketBeat
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock Price Book Value is a widely used stock evaluation measure. Find the latest Price Book Value for Aclaris Therapeutics, Inc. (ACRS) 1 day ago The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock